로딩 중…
지수 로딩 중…
Attovia Therapeutics Inc. Common Stock
ATTO· NASDAQ· Health Care
$16.21-0.61%
2026-10-09
Financials
Valuation Metrics
Attovia Therapeutics Inc. Common Stock's Market Cap is $740M. Ranked #2602 of 3,115 in US market (top 84%), #1104 of 1,464 on NASDAQ (top 75%) by Market Cap.
Investment Metrics(as of 2026-10-09)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $740M | US#2,602/3,115 |
| Revenue | $1M | US#2,846/3,115 |
| Net Income | $-61M | US—/3,115 |
| Total Assets | $166M | US#3,013/3,115 |
| Net Assets | $151M | US#2,739/3,115 |
| Employees | 44 | US#2,712/3,115 |
| Value | ||
| P/B | 4.63x | US#2,174/3,115 |
| P/S | 516.67x | US#2,977/3,115 |
| FCF Yield | -8.31% | US—/3,115 |
| Profitability | ||
| ROE | -40.21% | US#2,628/3,115 |
| ROA | -36.55% | US#2,926/3,115 |
| Op. Margin | -4974.74% | US#2,834/3,115 |
| Financial Health | ||
| Debt Ratio | 10.02% | US#108/3,115 |
| Total Debt | $5M | US#2,900/3,115 |
| FCF | $-62M | US#2,557/3,115 |
| Cash | $40M | US#2,668/3,115 |
| Current Ratio | 14.20x | US#175/3,115 |
| Performance | ||
| 1M Return | -29.09% | US#3,067/3,115 |
| From 52W High | -42.11% | US#2,437/3,115 |
| 1Y MDD | -36.56% | US#1,741/3,115 |
| Trading | ||
| Volume | 193,055 shares | US#1,984/3,115 |
| Trading Value | $3M | US#2,381/3,115 |
| Per Share | ||
| EPS | $-1.41 | US—/3,115 |
| BPS | $3.50 | US#2,414/3,115 |
Company Info
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.